- Home
- MNPR vs IBEX Comparison
MNPR vs IBEX Comparison
Compare MNPR & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | IBEX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.0M | 489.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNPR | IBEX |
|---|---|---|
| Price | $69.22 | $37.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 3 |
| Target Price | ★ $101.42 | $31.33 |
| AVG Volume (30 Days) | ★ 325.4K | 87.3K |
| Earning Date | 11-13-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.76 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $579,735,000.00 |
| Revenue This Year | N/A | $12.15 |
| Revenue Next Year | N/A | $5.68 |
| P/E Ratio | ★ N/A | $13.65 |
| Revenue Growth | N/A | ★ 12.86 |
| 52 Week Low | $24.00 | $21.05 |
| 52 Week High | $105.00 | $42.99 |
Technical Indicators
Market Signals| Indicator | MNPR | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 52.33 |
| Support Level | $57.86 | $37.32 |
| Resistance Level | $66.65 | $39.24 |
| Average True Range (ATR) | 5.60 | 1.18 |
| MACD | 0.99 | -0.07 |
| Stochastic Oscillator | 82.22 | 56.28 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About IBEX IBEX Limited
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.